TY - JOUR
T1 - Oral levodopa dose‐response study in MPTP‐induced hemiparkinsonian monkeys
T2 - Assessment with a new rating scale for monkey parkinsonism
AU - Kurlan, Roger
AU - Kim, Michael H.
AU - Gash, Don M.
PY - 1991
Y1 - 1991
N2 - Quantitative measures for the severity of MPTP‐induced parkinsonism and response to antiparkinsonian interventions in monkeys have been lacking. We carried out an oral levodopa dose‐response study in two rhesus monkeys whose left hemiparkinsonism was induced by intracarotid administration of MPTP. A newly developed clinical rating scale of monkey parkinsonism showed a consistent dose‐response relationship for levodopa over the dosage range of 50–3, 500 mg/day. Antiparkinsonian effects appeared at 200 mg/day and were optimal at 1,000–2,000 mg/day. Levodopa also reversed rotational behavior, improved movement times for both the impaired and opposite upper limb, and produced dyskinesias at high dosages. Thus, MPTP‐induced hemiparkinsonism in monkeys closely resembles the human disease condition, is associated with sensitive response measures, and should prove valuable for assessing novel antiparkinsonian therapies.
AB - Quantitative measures for the severity of MPTP‐induced parkinsonism and response to antiparkinsonian interventions in monkeys have been lacking. We carried out an oral levodopa dose‐response study in two rhesus monkeys whose left hemiparkinsonism was induced by intracarotid administration of MPTP. A newly developed clinical rating scale of monkey parkinsonism showed a consistent dose‐response relationship for levodopa over the dosage range of 50–3, 500 mg/day. Antiparkinsonian effects appeared at 200 mg/day and were optimal at 1,000–2,000 mg/day. Levodopa also reversed rotational behavior, improved movement times for both the impaired and opposite upper limb, and produced dyskinesias at high dosages. Thus, MPTP‐induced hemiparkinsonism in monkeys closely resembles the human disease condition, is associated with sensitive response measures, and should prove valuable for assessing novel antiparkinsonian therapies.
UR - http://www.scopus.com/inward/record.url?scp=0025906904&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025906904&partnerID=8YFLogxK
U2 - 10.1002/mds.870060205
DO - 10.1002/mds.870060205
M3 - Article
C2 - 2057003
AN - SCOPUS:0025906904
VL - 6
SP - 111
EP - 118
JO - Movement Disorders
JF - Movement Disorders
SN - 0885-3185
IS - 2
ER -